Adaptimmune Therapeutics PLC (ADAPY) stock

ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2025, quarter ended Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30

$0.04+0.00 (+9.38%)

Close on Oct 19, 2026Market cap $55.46MP/E –Yield –

Adaptimmune Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Adaptimmune Therapeutics's price to sales ratio was 0.9× on Oct 19, 2026, against 1.2× a year earlier. Over the last 5 years it ranged from 0.1× to 438.9×, with a median of 13.8×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Oct 19, 2026	0.9×	+0.2
2025	Dec 31, 2025	0.6×	−4.1
2024	Dec 31, 2024	4.7×	−10.5
2023	Dec 29, 2023	15.2×	−66.6
2022	Dec 30, 2022	81.8×	−322.4
2019	Dec 31, 2019	404.2×	+346.3
2018	Dec 31, 2018	57.9×	−322.5
2017	Dec 29, 2017	380.4×	+206.1
2016	Dec 30, 2016	174.3×	−214.7
2015	Nov 30, 2015	389.0×	–

Where these numbers come from

Parsed from the XBRL in Adaptimmune Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing